Synonyms: BMY-28142 | BMY28142 | CFPM | Maxipime® | Renapime®
cefepime is an approved drug (FDA (1996), UK (2017))
Compound class:
Synthetic organic
|
|
References |
1. Fuchs PC, Jones RN, Barry AL, Thornsberry C. (1985)
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother, 27 (5): 679-82. [PMID:3893316] |
2. Kaye KS, Belley A, Barth P, Lahlou O, Knechtle P, Motta P, Velicitat P. (2022)
Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. JAMA, 328 (13): 1304-1314. [PMID:36194218] |
3. Moeck G, Gasink LB, Mendes RE, Woosley LN, Dorr M, Chen H, Wagenlehner FM, Henkel T, McGovern PC. (2024)
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrob Agents Chemother, 68 (7): e0023624. [PMID:38780262] |
4. Tomatsu K, Ando S, Masuyoshi S, Hirano M, Miyaki T, Kawaguchi H. (1986)
Antibacterial activity of BMY-28142, a novel broad-spectrum cephalosporin. J Antibiot, 39 (11): 1584-91. [PMID:3539901] |
5. Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, Dane A, Henkel T, CERTAIN-1 Study Team. (2024)
Cefepime-Taniborbactam in Complicated Urinary Tract Infection. N Engl J Med, 390 (7): 611-622. [PMID:38354140] |